Osimertinib + Savolitinib
2 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Osimertinib + Savolitinib for carcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Osimertinib + Savolitinib for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |